Compare MasterCard Inc (MA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Recursion Pharmaceuticals Inc — how do they compare? MasterCard Inc trades at $586.3 (market cap $503.50B), while Recursion Pharmaceuticals Inc trades at $4.41 (market cap $2.14B). The key difference: MasterCard Inc is far larger — about 235.3× Recursion Pharmaceuticals Inc's market cap, and MasterCard Inc pays a 0.61% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MA | RXRX | |
|---|---|---|
Market Cap | $503.50B | $2.14B |
Volume | 3,390,859 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $599.86 | $6.79 |
52-Week Low | $471.55 | $2.84 |
Typical Hold Time | 134 Days | 22 Days |
Enterprise Value | $516.53B | $1.66B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $585.52, up 2.71% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 2025 revenue of $32.79B, net income margin of 46.34%, and impressive ROE of 241.49%. Recent institutional buying activity and positive analyst sentiment (80% buy ratings) support the stock's momentum as it approaches key resistance levels.
Mastercard presents a compelling growth opportunity with expanding digital payment adoption and strong financial performance, though elevated valuation multiples (P/E 31.6, P/S 14.7) and emerging payment technology competition warrant monitoring. The consensus price target of $666.67 suggests 14% upside potential from current levels.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
